Joinn Laboratories(China)Co.,Ltd.
6127.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.62B
Close$
$10.47
62.8% downside
Current Fair Value
62.8% downsideOvervalued by 62.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.62 Billion |
|---|---|
| Enterprise Value | $21.19 Billion |
| Dividend Yield | $0.14 (0.23%) |
| Earnings per Share | $0.4 |
| Beta | 0.8 |
| Outstanding Shares | 733,355,526 |
Return
| Return on Equity | 10.95% |
|---|---|
| Return on Assets | 9.07% |
| Return on Invested Capital | 4.48% |
Valuation & Multiples
| P/E Ratio | 39.64 |
|---|---|
| PEG | 1.61 |
| Price to Sales | 14.06 |
| Price to Book Ratio | 2.34 |
| Enterprise Value to Revenue | 12.53 |
| Enterprise Value to EBIT | 51.3 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$0.56
Average shareholder expectationRevenue Estimate
$445.87 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$457.21 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Joinn Laboratories(China)Co.,Ltd.
2,500 employees
CEO: Daniel Gao Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core...